{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:23:20Z","timestamp":1781663000753,"version":"3.54.5"},"reference-count":9,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.s666","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:11Z","timestamp":1776297611000},"page":"s666","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Multiple sclerosis: Could Roche\u2019s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?"],"prefix":"10.1136","volume":"393","author":[{"given":"Peter","family":"Doshi","sequence":"first","affiliation":[{"name":"The BMJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026041521002182000_393.apr15_13.s666.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103134"},{"key":"2026041521002182000_393.apr15_13.s666.2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.2565"},{"key":"2026041521002182000_393.apr15_13.s666.3","unstructured":"Food and Drug Administration. Drug approval package: Ocrevus (ocrelizumab) injection. 9 May 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761053Orig1s000TOC.html"},{"key":"2026041521002182000_393.apr15_13.s666.4","unstructured":"Food and Drug Administration. Citizen petition from Kaylin Bower. 5 Mar 2025. https:\/\/www.regulations.gov\/document\/FDA-2025-P-0547-0001"},{"key":"2026041521002182000_393.apr15_13.s666.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2026041521002182000_393.apr15_13.s666.6","unstructured":"Hoffmann-La Roche. A study to evaluate the efficacy and safety of ocrelizumab in adults with primary progressive multiple sclerosis (O\u2019HAND). 23 Feb 2026. https:\/\/clinicaltrials.gov\/study\/NCT04035005"},{"key":"2026041521002182000_393.apr15_13.s666.7","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.4607"},{"key":"2026041521002182000_393.apr15_13.s666.8","unstructured":"Committee on Oversight and Reform, Committee on Energy and Commerce. The high price of Aduhelm\u2019s approval: an investigation into FDA\u2019s atypical review process and Biogen\u2019s aggressive launch plans. 2022. https:\/\/democrats-energycommerce.house.gov\/sites\/evo-subsites\/democrats-energycommerce.house.gov\/files\/documents\/Final%20Aduhelm%20Report_12.29.22.pdf"},{"key":"2026041521002182000_393.apr15_13.s666.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p73"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.s666","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.s666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:00:33Z","timestamp":1776312033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.s666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":9,"alternative-id":["10.1136\/bmj.s666"],"URL":"https:\/\/doi.org\/10.1136\/bmj.s666","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}